Managing Director, BCRF Venture Philanthropy Program

About Bcrf
Breast cancer is a complex disease with no simple solution. Research is the key to stopping it in its tracks. Founded in 1993 by Evelyn H. Lauder, the Breast Cancer Research Foundation is the largest private funder of breast cancer research in the world. By investing in the best minds in science to examine every aspect of the disease from prevention to metastasis—and fostering cross-disciplinary collaboration—BCRF is accelerating the entire field and moves us closer to the answers we urgently need to be the end of breast cancer.
Since its founding in 1993, BCRF has invested more than $1 billion in research, supporting a global network of over 280 scientists across 18 countries. With annual grant disbursements reaching a record $75 million in 2026–2027, BCRF-funded investigators have contributed to the discoveries underlying multiple FDA-approved therapies and diagnostic tools that have collectively driven a 44% reduction in breast cancer deaths since 1989.
Despite this scale and impact, a persistent translational gap remains between BCRF-funded discovery science and the capital-intensive clinical development activities that carry new diagnostics and therapies to patients. Commercial venture capital has shifted decisively toward later-stage, de-risked assets, leaving pre-clinical and Phase I programs — precisely where many of BCRF's most promising discoveries sit — chronically underfunded.
To close that gap, BCRF has established the BCRF Venture Philanthropy Program (the "Program"), an evergreen investment vehicle that will deploy $100 million over five to seven years into early- and mid-stage companies advancing breast cancer therapeutics, diagnostics, and prevention technologies. The Program is modeled on the proven success of peer disease-focused ventur

关于Bcrf
乳腺癌是一种复杂的疾病，没有简单的解决方案。研究是阻止其发展的关键。乳腺癌研究基金会由Evelyn H. Lauder于1993年创立，是全球最大的乳腺癌研究私人资助机构。通过投资于科学界最优秀的人才，研究从预防到转移的疾病各个方面——并促进跨学科合作——BCRF正在加速整个领域的发展，使我们更接近终结乳腺癌所迫切需要的答案。
自1993年成立以来，BCRF已在研究上投入超过10亿美元，支持覆盖18个国家、280多名科学家的全球网络。随着年度拨款在2026–2027年达到创纪录的7500万美元，BCRF资助的研究人员为多项FDA批准疗法和诊断工具背后的发现做出了贡献，这些成果共同推动了自1989年以来乳腺癌死亡率下降44%。
尽管具有这样的规模和影响力，BCRF资助的发现科学与将新诊断工具和疗法带给患者的资本密集型临床开发活动之间仍然存在持续性的转化缺口。商业风险投资已决定性地转向后期、风险已降低的资产，使得临床前和I期项目——恰恰是BCRF许多最有前景的发现所在之处——长期资金不足。
为弥合这一缺口，BCRF设立了BCRF Venture Philanthropy Program（“该Program”），这是一个永续投资工具，将在五到七年内投入1亿美元，用于推进乳腺癌治疗、诊断和预防技术的早期和中期公司。该Program以同类疾病聚焦型风险投资

⚑ 岗位信息收录自公开招聘页（公开招聘平台），以雇主官网为准